Certara’s (CERT) “Overweight” Rating Reaffirmed at Stephens

Stephens restated their overweight rating on shares of Certara (NASDAQ:CERT) in a research note released on Thursday,Benzinga reports. The brokerage currently has a $17.00 target price on the stock.

A number of other brokerages have also recently issued reports on CERT. Robert W. Baird dropped their target price on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a report on Tuesday, November 5th. TD Cowen assumed coverage on shares of Certara in a report on Thursday. They issued a “buy” rating and a $16.00 target price for the company. Finally, Barclays dropped their target price on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday, November 7th. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Certara currently has a consensus rating of “Moderate Buy” and an average target price of $15.83.

Certara Trading Down 3.4 %

NASDAQ CERT opened at $11.98 on Thursday. The stock has a market capitalization of $1.93 billion, a P/E ratio of -59.90, a P/E/G ratio of 9.29 and a beta of 1.57. Certara has a 52-week low of $9.41 and a 52-week high of $19.87. The firm has a 50-day moving average price of $12.45 and a 200 day moving average price of $11.63. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28.

Hedge Funds Weigh In On Certara

Several hedge funds and other institutional investors have recently made changes to their positions in CERT. Blue Trust Inc. increased its position in shares of Certara by 112.3% in the 3rd quarter. Blue Trust Inc. now owns 3,925 shares of the company’s stock worth $46,000 after purchasing an additional 2,076 shares during the last quarter. Harbor Capital Advisors Inc. boosted its stake in Certara by 18.4% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 20,144 shares of the company’s stock valued at $236,000 after purchasing an additional 3,136 shares during the period. Atria Investments Inc boosted its stake in Certara by 21.6% during the 3rd quarter. Atria Investments Inc now owns 19,743 shares of the company’s stock valued at $231,000 after purchasing an additional 3,501 shares during the period. TimesSquare Capital Management LLC boosted its stake in Certara by 3.1% during the 3rd quarter. TimesSquare Capital Management LLC now owns 956,655 shares of the company’s stock valued at $11,202,000 after purchasing an additional 29,090 shares during the period. Finally, Versor Investments LP acquired a new stake in shares of Certara in the 3rd quarter worth approximately $162,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.